fashion -WSS

fashion

author：Wikipedia 2025-09-29 07:29:14 - browse：45189

As a new class of diabetes and obesity medications has soared in popularity, so have the online outlets built to get them in the hands of patients. A new analysis of claims data from Trilliant Health suggests that collectively, telehealth companies — in particular, cash-pay options that market directly to consumers — could account for many of the patients with insurance claims for GLP-1 prescriptions in 2022.

Direct-to-consumer telehealth companies have offered an easier on-ramp for many patients to access prescriptions for a variety of conditions. And since the first GLP-1s were approved for obesity — promising up to 15% weight loss — many of those companies have capitalized on the approvals and surging demand to launch new weight loss businesses. Companies including Calibrate and Ro claim to have reached tens and hundreds of thousands of patients with their weight loss medication programs.

Collectively, their reach may be even larger. The Trilliant Health analysis, conducted on behalf of STAT, offers an early glimpse of the foothold those businesses have gained in GLP-1 prescribing. In a nationwide claims database of more than 300 million patients using both commercial and federal insurance, Trilliant Health found about 3.6 million people with a prescription claim for a GLP-1 — semaglutide, tirzepatide, or injectable liraglutide without insulin — in 2022. To determine where each patient may have gotten those prescriptions, they looked for a medical visit claim within three days of a prescription claim for a GLP-1 — the visit where the script was likely written. But they only found a matching visit for 53% of patients.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

hotspot

WSS

David Sabatini, ex

Weight loss drug costs may need more research, senator suggests

Weight loss drug costs may need more research, senator suggests

Why depression after traumatic brain injury is distinct

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

FDA advisers back CAR

entertainment

fashion

knowledge

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Hospitals look to new technology to keep health care workers safe

Psychedelics group wrestles with new pharma identity

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

Wildfire smoke exposes gaps in outdoor worker protections

Male and female sex labels in research insufficient, scientists say

Bright Health sells Medicare Advantage business to Molina

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

Wildfire smoke exposes gaps in outdoor worker protections

Poor hospice wound care hurts patients and families

hotspot

NYU radiologists take on the challenge of expensive MRI machines

Hospitals look to new technology to keep health care workers safe

Anthos stroke drug appears safer than common blood thinner

John Green on his newest strategy for fighting tuberculosis

Why medical students are struggling with mental health

Readout Newsletter: Bristol, Sangamo, Gilead, and more

hotspot

hotspot

knowledge

focus